Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 3;14:588. doi: 10.1038/s41467-023-36193-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a The percentage of Variant Allele Frequency (VAF) for the mutations of TET2 observed in the white mononuclear cells (WMC) and in sorted NK/T cells at diagnosis of TET2^MUT MDS/CMML patients (n = 10) was evaluated by NGS analysis (with a range from 1 to 4 mutations per patient). Data are represented as box-and-whisker plots (minimum VAF, 25% percentile, median, 75% percentile, and maximum VAF respectively for WMC: 0%, 11.25%, 32.5%, 42.5%, 49%; for NK cells: 0%, 3.5%, 14%, 35.5%, 54%; and for T cells: 0%, 0%, 0%, 0%, 7%). Nonparametric two-sided Wilcoxon matched-pairs signed rank test was used to determine statistical significance. ****p < 0.0001. b VAF (%) of the different mutations detected in the WMC at diagnosis (blue) and in sorted NK cells (red) in 4 patients (MUT08, MUT22, MUT19, MUT31; see Supplementary Table 6 for more information). c Correlation curve between the percentage of KIR2D⁺ NK cells and the TET2 VAF (%) in blood NK cells from the MDS/CMML patients analyzed in (a). Linear regression was calculated, r = 0.88, p < 0.0001. d The VAF percentage in the WMC and in sorted KIR+ and KIR− NK cells at diagnosis from TET2^MUT MDS/CMML patients (n = 5, range from 1 to 4 mutations per patient) was evaluated by NGS analysis. Data are represented as box-and-whisker plots (minimum VAF, 25% percentile, median, 75% percentile, and maximum VAF respectively for KIR− NK cells: 6.1%, 8.3%, 18.2%, 36.5%, 42.1%; and KIR+ NK cells: 0%, 1.2%, 7.3%, 13%, 48%). Statistics were calculated with a two-sided nonparametric Wilcoxon matched-pairs signed rank test. *p = 0.0186. Source data are provided as a Source Data file.